Ketosis, MetabolicNCT05103761
Effect of Diet Induced Ketosis on LDL Turnover Rates
A study testing Study diet and Low glycemic index treatment diet in people with Ketosis, Metabolic, run by University Health Network, Toronto at 1 site in Canada.
Trial summary
There have been concerning case reports of marked elevations of LDL-c in some individuals consuming a KD and Dr. Lewis has been referred a number of these cases to his lipid clinic, some of whom have had extreme elevations of LDL that mimic familial hypercholesterolemia. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Ketosis, Metabolic
- What is being tested?
- Study diet and Low glycemic index treatment diet
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 24 participants
- Where
- 1 siteCanada
- Study dates
- 12 Oct 2021to 30 Jun 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Men and women aged 18 to 65 years
- Normolipidemic
- Plasma TG <2.0 mmol/L (~175 mg/dL)
- HDL >1.0 mmol/L (~40 mg/dL) ) in men or >1.3 mmol/L (50 mg/dL) in women
- LDLc <4.0 mmol/L (~150 mg/dL)
- Total cholesterol <5.0 mmol/L (~200 mg/dL)
Show all 16Show fewer
- Blood pressure ≤ 140/90 mmHg
- Fasting plasma glucose ≤ 6.3 mmol/L (125 mg/dL)
- HbA1c within ≥ 4.0% to ≤ 6.0%
- Hb > 130
- BMI between 18-30 kg/m2
- Participant agrees to maintain their usual lifestyle and not make any significant changes to activity levels while enrolled in the study
- Cr < 110 umol
- Able to speak and read English
- Agrees to consume each study diet for eight weeks
- Agrees to refrain from alcohol consumption 12 hours before the study
Who cannot join
- Patients on active treatment using lipid-lowering medications, such as statins, ezetimibe, or bile acid sequestrants
- Use of medications that interfere with protein, carbohydrate, or lipid metabolism (e.g., fish oil capsules)
- Patients who have unstable weight in the past three months (weight loss)
- Patients with a history of gout
- Patients who have had major surgeries
- Abnormal thyroid function or known liver disease
Show all 17Show fewer
- Patients with chronic kidney disease, decompensated liver disease, unstable cardiac or respiratory disease, or GFR
- Uncontrolled hypertension
- Patients who are pregnant or breastfeeding or peri-menopausal
- Actively attempting to get pregnant or pregnant. Low dose estrogen-containing pill if taken for > 3 months and continued throughout the study is acceptable. Women will be required to use adequate contraception and a pregnancy test will be performed on all women at the time of screening and immediately before each kinetics study.
- Participant has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose additional risk to the participant by their participation in the study.
- Abnormal bleeding, frequent headaches, arthritis, stomach problems, SOB, migraines, black outs/fainting, epilepsy, chest pain, asthma
- Participants who consume vegan diet
- Participant consumes excessive amounts of alcohol, defined as >70 g/wk (5 standard drink/wk) for female, and >140 g/wk (10 standard drink/wk) for male.
- One standard drink contains roughly 14 grams of pure alcohol, which is found in: 12 ounces of regular beer, 5 ounces of wine or 1.5 ounces of distilled spirits. Vigorous-intensity physical activity, defined as more than 150 minutes per week of moderate-intensity, or 75 minutes a week of vigorous-intensity aerobic physical activity, or an equivalent combination of both.
- Participant has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks prior to the prestudy visit.
- Participants have an upcoming special event during the study (wedding, vacation travel, etc.).
Trial locations and contacts
1 site in 1 country.
Canada1 site, 1 recruiting
- Recruiting
Tornto General Hospital, UHN
Toronto, Ontario, M5G 1L7
Brenda Hughes, RN, 416-340-8886, brenda.hughes@uhn.ca
Gary F Lewis, MD
About this study
Official title: Measuring Low-density Lipoprotein Particle Production and Clearance Rates in Response to Diet-induced Ketosis in Humans
There have been concerning case reports of marked elevations of LDL-c in some individuals consuming a KD and Dr. Lewis has been referred a number of these cases to his lipid clinic, some of whom have had extreme elevations of LDL that mimic familial hypercholesterolemia. These marked elevations of LDLc are unique to a ketogenic diet and far exceed the typical mild elevations seen in those consuming a high fat, low carbohydrate LGIT. The degree of elevation of LDL-c suggests that ketosis per se may impair LDL receptor-mediated LDL particle clearance. This clinical observation is a concerning and clinically important issue since millions of people are consuming this popular diet. There are currently no studies that have examined the mechanism of the LDL-raising effect of a ketogenic diet.
Read the detailed description
A ketogenic diet (KD) has recently gained popularity amongst the public due to its ability to induce rapid weight loss and for a number of other putative but unproven health benefits. Ketogenic diets also have proven efficacy in resistant cases of seizure disorders. However, due to palatability and adherence issues with KD, alternative diets like the less extreme low glycemic index treatment (LGIT) diet have been effectively used as a seizure disorder treatment option. KD primarily restricts the total amount of carbohydrates in the diet to ≤10% of total caloric intake whereas LGIT primarily restricts high glycemic index foods with total carbohydrates constituting 15% of total energy consumption. While several benefits have been outlined previously, conflicting results have been observed on the effect of diet-induced ketosis on plasma concentrations of the atherogenic low-density lipoprotein cholesterol (LDLc). While some studies showed a significant increase in LDLc with KD treatment, other studies reported the opposite effects with some studies reporting no difference.
Of the studies that reported an increase in LDLc, a review conducted by Chawla et al reported that restricting carbohydrates did not lower LDLc compared to a low-fat diet. In fact, the studies that utilized a low carbohydrate diet reported a significant increase in plasma LDLc concentrations. Similar results were observed by others who reported a significant increase in plasma LDLc within 3 weeks, six months, and 12 months of KD, respectively. Contrary to these findings, Dashti et al reported a significant reduction in plasma LDLc within eight weeks of KD, which remained lower for 24 weeks. Interestingly, in a study conducted by Luukkonen et al, six weeks of KD did not result in any changes in the plasma LDLc. Similar findings were reported by others. With regard to the effect of KD on apoB, limited studies reported that KD increased apoB in the pediatric population but resulted in no change in plasma apoB concentration in adults
. Importantly, there have been concerning case reports of marked elevations of LDL-c in some individuals consuming a KD and Dr. Lewis has been referred a number of these cases to his lipid clinic, some of whom have had extreme elevations of LDL that mimic familial hypercholesterolemia. These marked elevations of LDLc are unique to a ketogenic diet and far exceed the typical mild elevations seen in those consuming a high fat, low carbohydrate LGIT. The investigators speculate that there may be metabolic effects of ketosis per se, independent of the macronutrient composition of the diet that could impair LDL clearance or increase its production. Hence our interest in comparing the effects on LDL metabolism of two low carbohydrate, high-fat diets, differing in their degree of carbohydrate restriction, with and without ketosis. Of course, the investigators cannot completely match the macronutrient composition of the two diets, but the diets will be matched as closely as possible apart from maintaining carbohydrates below or just above the ketogenic threshold, respectively.
Since the popularity of ketogenic diets has increased exponentially amongst the general public in recent years and is commonly used for the treatment of epilepsy, a significant increase in atherogenic LDL-c concentration in those consuming KD could have important public health ramifications. Based on previous literature, at least 1/3rd of the individuals following KD have reported a marked elevation in LDLc levels. Whether this marked elevation in LDLc is due to excess production of LDLc or a defect in clearance is unknown. Due to the complexities and difficulties in quantitating synthesis and clearance rates for LDLc, no studies have been conducted to investigate the changes in LDLc kinetics in response to KD.
- Conditions
- Ketosis, Metabolic
- Being tested
- Study diet, Low glycemic index treatment diet
- Keywords
- keto diet, ketosis, LDL metabolism, hyperlipidemia, cardiovascular disease
- Medical subject headings
- Ketosis, Hyperlipidemias, Cardiovascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Study dietOther
Also called Nutritional intervention
A low carbohydrate diet (<20g/day) is administered to achieve diet-induced ketosis.
Low glycemic index treatment dietOther
Also called Control
A diet matched with the study diet with added carbohydrates (40-60g/day) to avoid ketosis.
| Study group | Role | What they receive |
|---|---|---|
| Ketogenic diet | Active comparator | Diet administered to induce ketosis. Receives: Other: Study diet |
| Low glycemic index treatment diet | Placebo comparator | Diet matched with a ketogenic diet with added carbohydrates to avoid ketosis. Receives: Other: Low glycemic index treatment diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
LDL apoB turnover rates
The primary objective is to quantitate LDL apoB turnover rates in response to eight weeks of KD-induced ketosis in healthy individuals.
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Nov 2021
- Study start12 Oct 2021
- Primary completion31 Dec 2022 (estimated)
- Study completion30 Jun 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ketosis, MetabolicStudies of the same condition, open and under way.
- More trials run by University Health Network, TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Participants will be randomly assigned to either the ketogenic diet or the LGIT diet for 8 weeks. Once they complete the first diet, they will go under a washout period for 8 weeks before they start the second diet.
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Gary F Lewis, MD, Principal investigator, University Health Network, Toronto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05103761
- Sponsor's protocol ID
- Keto study 21-5376
- Status last verified
- Oct 2021
- First submitted
- 21 Oct 2021
- Last updated
- 9 Nov 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No plans to share IPD with other researchers.
Study at a glance
From the registry record, last updated by the sponsor on 9 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Measuring Low-density Lipoprotein Particle Production and Clearance Rates in Response to Diet-induced Ketosis in Humans
- ClinicalTrials.gov ID
- NCT05103761
- Acronym / sponsor ID
- Keto study 21-5376
- Conditions
- Ketosis, Metabolic
- Keywords
- keto diet, ketosis, LDL metabolism, hyperlipidemia, cardiovascular disease
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- University Health Network, TorontoUniversity, hospital or other
- Study start
- 12 Oct 2021 (actual)
- Primary completion
- 31 Dec 2022 (estimated)
- Study completion
- 30 Jun 2023 (estimated)
- First posted
- 2 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
There have been concerning case reports of marked elevations of LDL-c in some individuals consuming a KD and Dr. Lewis has been referred a number of these cases to his lipid clinic, some of whom have had extreme elevations of LDL that mimic familial hypercholesterolemia. These marked elevations of LDLc are unique to a ketogenic diet and far exceed the typical mild elevations seen in those consuming a high fat, low carbohydrate LGIT. The degree of elevation of LDL-c suggests that ketosis per se may impair LDL receptor-mediated LDL particle clearance. This clinical observation is a concerning and clinically important issue since millions of people are consuming this popular diet. There are currently no studies that have examined the mechanism of the LDL-raising effect of a ketogenic diet.
Detailed description
A ketogenic diet (KD) has recently gained popularity amongst the public due to its ability to induce rapid weight loss and for a number of other putative but unproven health benefits. Ketogenic diets also have proven efficacy in resistant cases of seizure disorders. However, due to palatability and adherence issues with KD, alternative diets like the less extreme low glycemic index treatment (LGIT) diet have been effectively used as a seizure disorder treatment option. KD primarily restricts the total amount of carbohydrates in the diet to ≤10% of total caloric intake whereas LGIT primarily restricts high glycemic index foods with total carbohydrates constituting 15% of total energy consumption. While several benefits have been outlined previously, conflicting results have been observed on the effect of diet-induced ketosis on plasma concentrations of the atherogenic low-density lipoprotein cholesterol (LDLc). While some studies showed a significant increase in LDLc with KD treatment, other studies reported the opposite effects with some studies reporting no difference.
Of the studies that reported an increase in LDLc, a review conducted by Chawla et al reported that restricting carbohydrates did not lower LDLc compared to a low-fat diet. In fact, the studies that utilized a low carbohydrate diet reported a significant increase in plasma LDLc concentrations. Similar results were observed by others who reported a significant increase in plasma LDLc within 3 weeks, six months, and 12 months of KD, respectively. Contrary to these findings, Dashti et al reported a significant reduction in plasma LDLc within eight weeks of KD, which remained lower for 24 weeks. Interestingly, in a study conducted by Luukkonen et al, six weeks of KD did not result in any changes in the plasma LDLc. Similar findings were reported by others. With regard to the effect of KD on apoB, limited studies reported that KD increased apoB in the pediatric population but resulted in no change in plasma apoB concentration in adults
. Importantly, there have been concerning case reports of marked elevations of LDL-c in some individuals consuming a KD and Dr. Lewis has been referred a number of these cases to his lipid clinic, some of whom have had extreme elevations of LDL that mimic familial hypercholesterolemia. These marked elevations of LDLc are unique to a ketogenic diet and far exceed the typical mild elevations seen in those consuming a high fat, low carbohydrate LGIT. The investigators speculate that there may be metabolic effects of ketosis per se, independent of the macronutrient composition of the diet that could impair LDL clearance or increase its production. Hence our interest in comparing the effects on LDL metabolism of two low carbohydrate, high-fat diets, differing in their degree of carbohydrate restriction, with and without ketosis. Of course, the investigators cannot completely match the macronutrient composition of the two diets, but the diets will be matched as closely as possible apart from maintaining carbohydrates below or just above the ketogenic threshold, respectively.
Since the popularity of ketogenic diets has increased exponentially amongst the general public in recent years and is commonly used for the treatment of epilepsy, a significant increase in atherogenic LDL-c concentration in those consuming KD could have important public health ramifications. Based on previous literature, at least 1/3rd of the individuals following KD have reported a marked elevation in LDLc levels. Whether this marked elevation in LDLc is due to excess production of LDLc or a defect in clearance is unknown. Due to the complexities and difficulties in quantitating synthesis and clearance rates for LDLc, no studies have been conducted to investigate the changes in LDLc kinetics in response to KD.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Participants will be randomly assigned to either the ketogenic diet or the LGIT diet for 8 weeks. Once they complete the first diet, they will go under a washout period for 8 weeks before they start the second diet.
| Arm | Type | Receives |
|---|---|---|
| Ketogenic diet | Active comparator | Other: Study dietDiet administered to induce ketosis. |
| Low glycemic index treatment diet | Placebo comparator | Other: Low glycemic index treatment dietDiet matched with a ketogenic diet with added carbohydrates to avoid ketosis. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Men and women aged 18 to 65 years
- Normolipidemic
- BMI between 18-30 kg/m2
- Participant agrees to maintain their usual lifestyle and not make any significant changes to activity levels while enrolled in the study
- Cr < 110 umol
Key exclusion criteria (17 listed)
- Patients on active treatment using lipid-lowering medications, such as statins, ezetimibe, or bile acid sequestrants
- Use of medications that interfere with protein, carbohydrate, or lipid metabolism (e.g., fish oil capsules)
- Patients who have unstable weight in the past three months (weight loss)
- Patients with a history of gout
- Patients who have had major surgeries
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Study dietAlso: Nutritional interventionA low carbohydrate diet (<20g/day) is administered to achieve diet-induced ketosis. | Other | Ketogenic diet |
| Low glycemic index treatment dietAlso: ControlA diet matched with the study diet with added carbohydrates (40-60g/day) to avoid ketosis. | Other | Low glycemic index treatment diet |
Primary outcome
LDL apoB turnover rates
Time frame: 8 weeks
The primary objective is to quantitate LDL apoB turnover rates in response to eight weeks of KD-induced ketosis in healthy individuals.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Nov 2021.
- Individual participant dataSharing planned: No. No plans to share IPD with other researchers.
Related trials for Ketosis, Metabolic
RecruitingPhase 2/3
Effects of Ketone Supplementation on Alcohol Withdrawal and Brain Metabolism in Alcohol Use Disorder
Alcohol Use Disorder, Alcohol Withdrawal
Recruiting
Variations in Ketone Metabolism
Ketosis
Not yet recruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
Healthy Volunteers and Diabetes Participants
Recruiting
LIfestyle MEtabotype Study B (LIME-B)
Nutritional and Metabolic Diseases, Prediabetes
RecruitingObservational study
Health, Imaging, and Cognition Across the Menopausal Transition
Menopause
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gary F Lewis, MD principal investigator
University Health Network, Toronto
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Study diet and Low glycemic index treatment diet in people with Ketosis, Metabolic, run by University Health Network, Toronto at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Gary F Lewis, MD (416-340-4270, gary.lewis@uhn.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
LDL apoB turnover rates (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2021.